Navigation Links
Martek Announces First Quarter 2008 Financial Results
Date:3/5/2008

products with reasonable profit margins or those that the Company expects could have a strategic fit in the future.

Gross Margin and Operating Expenses

Gross margin for the first quarter of fiscal 2008 was 41.1%, an increase over both the 34.0% gross margin realized in the first quarter of fiscal 2007 and the 40.2% gross margin realized in the fourth quarter of 2007, which included a non-recurring property tax recovery that contributed approximately 1% to gross margin. This gross profit margin improvement resulted from DHA productivity gains at Martek's manufacturing facilities, as well as reductions in ARA costs.

Research and development expenses in the first quarter of fiscal 2008 were $6.0 million, essentially unchanged from the first quarter of fiscal 2007. The Company's research and development efforts continue to focus on developing new food and beverage applications for life'sDHA(TM), broadening the scientific evidence supporting the benefits of life'sDHA(TM) throughout life, improving manufacturing processes and developing new products to expand the Company's market offerings. The Company will experience quarter-to-quarter fluctuations in research and development expenses primarily due to the timing of outside services, including third-party clinical trial services.

During the first quarter of fiscal 2008, selling, general and administrative expenses increased to $13.0 million, a $2.3 million increase from last year's first quarter. As a percentage of revenue, the Company's selling, general and administrative expenses increased to 15.7% in the first quarter of fiscal 2008 from 15.1% in last year's first quarter. The Company continues to invest resources in areas needed to support its growth. Furthermore, Martek continues to incur costs for marketing initiatives, which vary based on the timing of such marketing campaigns, and which are mainly designed to increase sales to infant formula customers overseas and to grow DHA markets ou
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Marteks lifesDHA(TM) Featured in Three New Offerings of Baby Food from Plum Organics
2. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
3. Pocket Rocket Juice from Australias Boost Juice Features 700 mg of Marteks lifesDHA(TM)
4. Martek Announces Settlement of Class Action Lawsuit
5. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
6. Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International
7. Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinovas Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements
8. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
9. Martek Signs Multi-Year Infant Formula License and Supply Agreement with Alter Farmacia
10. Martek Announces Addition of lifesDHA(TM) to Entire Bellybar(TM) Line of Nutrition Bars
11. Martek Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... now widespread in just one state, but a resurgence could ... -- As the H1N1 swine flu outbreak eases to ... state, federal health officials are still urging Americans to get ... Influenza Vaccination Week," Kathleen Sebelius, Secretary of the U.S. Department ...
... , NEWBURGH, N.Y., Jan. 8 "I hope I ... need help and to offer them advice and guidance." , So said ... Mary College, is one of the many students who have made psychology ... Mount also has many students who pursue careers in education, taking a ...
... treatment with the natural compound Quercetin , FRIDAY, Jan. ... that play an important role in hepatitis C infection, and ... toxic treatments for the disease, which can lead to cirrhosis ... are interferon and ribavirin, which can cause major side effects ...
... , , - Subtle Language ... PHILADELPHIA, Jan 8 Children with autism spectrum disorders (ASDs) process ... without ASDs, and measuring magnetic signals that mark this delay may ... http://www.newscom.com/cgi-bin/prnh/20100108/DC34671 ) , Researchers at The Children,s Hospital of ...
... Jan. 8 Gilbert Hospital continued to exceed expectations in ... emergency department, patient levels remained constant compared to 2008. ... continued its success with more than 98.5% of emergency room ... minutes of arrival. Additionally, the average wait time in 2009 ...
... ... to be presented at 32nd annual San Antonio Breast Cancer Symposium , ... Los Angeles, ... biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® ...
Cached Medicine News:Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 2Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 3Health News:Psychology Popular Among College Students 2Health News:Psychology Popular Among College Students 3Health News:Psychology Popular Among College Students 4Health News:Psychology Popular Among College Students 5Health News:Key to Hepatitis C May Be Two Cellular Proteins 2Health News:Brain Imaging May Help Diagnose Autism 2Health News:Brain Imaging May Help Diagnose Autism 3Health News:Brain Imaging May Help Diagnose Autism 4Health News:Gilbert Hospital 2009 Emergency Department Year in Review 2Health News:Abraxis Provides Overview Of ABRAXANE Study 2Health News:Abraxis Provides Overview Of ABRAXANE Study 3
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately held company ... disease (AD) and related neurodegenerative disorders, announced today the ... NY as of January 15, 2014 and ... York Medical College. Oligomerix, which is focused ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Homeostasis Effects in,Normal and Diabetic Rats --, CHICAGO, ... IIa study of the safety profile of multiple ... of,the Sodium-Glucose Transporter 2 (SGLT2) administered alone or,concomitantly ... no,discontinuations due to adverse events and no serious ...
... June 25, 2007 /PRNewswire/ -- Novagali Pharma, an,emerging ... its pivotal phase III clinical trial,positive results from ... suffering from Vernal Keratoconjunctivitis (VKC) at the,XIV Afro-Asian ... 25 2007 in Marrakech (Morocco). , VKC is ...
Cached Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
Inquire...
Inquire...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Medicine Products: